Expert Review of Clinical Immunology最新文献_第6页

Organ damage in systemic sclerosis: linking immune activation, vasculopathy, and fibrosis to precision treatment. 系统性硬化症的器官损害：将免疫激活、血管病变和纤维化与精确治疗联系起来。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-05-01 Epub Date: 2026-05-21 DOI: 10.1080/1744666X.2026.2675635

Judith Potjewijd, Rachid Tobal, Jan G M C Damoiseaux, Pieter van Paassen

{"title":"Organ damage in systemic sclerosis: linking immune activation, vasculopathy, and fibrosis to precision treatment.","authors":"Judith Potjewijd, Rachid Tobal, Jan G M C Damoiseaux, Pieter van Paassen","doi":"10.1080/1744666X.2026.2675635","DOIUrl":"10.1080/1744666X.2026.2675635","url":null,"abstract":"Introduction: Systemic sclerosis (SSc) is a severe autoimmune disease associated with progressive multi-organ damage and increased mortality. Although fibrosis characterizes advanced stages, early disease is marked by immune dysregulation and microvascular injury that precede irreversible organ damage. Failure to recognize these early pathogenic processes contributes to delayed treatment initiation and poorer clinical outcomes.Areas covered: This review integrates current insights into the mechanisms driving organ damage in SSc, focusing on the interaction between inflammatory, vascular, and tissue-remodeling processes. Organ-specific manifestations affecting the skin, lungs, heart, kidneys, and gastrointestinal tract are discussed. We examine established and emerging biomarkers reflecting inflammatory, vascular, and fibrotic activity, including interferon-related signatures, soluble immune checkpoints, extracellular matrix turnover markers, extracellular vesicle profiles, and dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP). In addition, targeted therapeutic strategies aligned with these pathogenic pathways are reviewed.Expert opinion: SSc is a biologically heterogeneous disease in which the relative contribution of inflammation, vascular dysfunction, and fibrosis varies between patients and across disease stages. Effective management requires early identification of the dominant disease process to guide therapy. Biomarker-informed stratification and mechanism-based treatment approaches may shift care from late-stage organ protection toward earlier disease modification and prevention of irreversible damage.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"463-479"},"PeriodicalIF":4.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Authors response: other autoimmune disorders in chronic immune-mediated neuropathies: why trying to find out does matter. 作者的回应：慢性免疫介导的神经病变中的其他自身免疫性疾病：为什么试图找出它很重要。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-05-01 Epub Date: 2026-05-25 DOI: 10.1080/1744666X.2026.2677309

Chinar Osman, Yusuf A Rajabally, Young Gi Min, Joumana Freiha

引用次数: 0

Harnessing the immune system in lung cancer: emerging role of the microbiome. 利用免疫系统治疗肺癌：微生物组的新作用。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-05-01 Epub Date: 2026-05-17 DOI: 10.1080/1744666X.2026.2661805

Ghazal Roostaei, Taghi Riahi, Shekoufeh Nikfar, Mohammad Abdollahi

{"title":"Harnessing the immune system in lung cancer: emerging role of the microbiome.","authors":"Ghazal Roostaei, Taghi Riahi, Shekoufeh Nikfar, Mohammad Abdollahi","doi":"10.1080/1744666X.2026.2661805","DOIUrl":"10.1080/1744666X.2026.2661805","url":null,"abstract":"Introduction: The microbiome has emerged as a critical regulator of tumor biology and immune response in lung cancer. Once considered sterile, the lung is now recognized to harbor a diverse microbiome that interacts with the gut-lung axis to shape inflammation, immune evasion, and therapeutic outcomes.Areas covered: This study reviews current evidence linking microbiome composition and function to lung cancer development and response to immune checkpoint inhibitors (ICIs). We explore mechanisms of microbial influence on host immunity, identify key taxa associated with treatment outcomes, and summarize therapeutic strategies such as fecal microbiota transplantation, probiotics, postbiotics, dietary changes, antibiotics, and engineered live biotherapeutics. The literature search was performed across multiple databases and sources, including PubMed, Scopus, Embase, and clinical trial registries, up to August 2025, focusing on both preclinical and clinical studies related to lung cancer, immunotherapy, and microbiome-targeted interventions.Expert opinion: Microbiome research is redefining precision oncology by presenting new biomarkers and therapeutic targets. Although early-phase trials show potential to improve ICI efficacy, implementation is limited by donor variability, methodological differences, and biosafety issues. Standardized protocols, mechanistic studies, and biomarker-driven patient selection will be crucial to incorporating microbiome modulation into routine lung cancer treatment.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"557-574"},"PeriodicalIF":4.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147940705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy and reproductive care in Behçet's disease: clinical excellence across the maternal journey. behet病的妊娠和生殖保健：整个产妇旅程的临床卓越。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-05-01 Epub Date: 2026-05-06 DOI: 10.1080/1744666X.2026.2669542

Ghaydaa Aldabie, Ahlam Almarzooqi, Shamma Al Nokhatha, Wesam Gouda, Mohammad Khudadah, Rawan Saleh, Maher Banjari, Roaa Aljohani, Samar Al-Emadi, Ali Jawad

{"title":"Pregnancy and reproductive care in Behçet's disease: clinical excellence across the maternal journey.","authors":"Ghaydaa Aldabie, Ahlam Almarzooqi, Shamma Al Nokhatha, Wesam Gouda, Mohammad Khudadah, Rawan Saleh, Maher Banjari, Roaa Aljohani, Samar Al-Emadi, Ali Jawad","doi":"10.1080/1744666X.2026.2669542","DOIUrl":"10.1080/1744666X.2026.2669542","url":null,"abstract":"Introduction: Behçet's disease (BD) is a rare, multisystem inflammatory disorder predominantly affecting women during their reproductive years. Its potential impact on pregnancy outcomes makes understanding optimal management strategies crucial. Given the complexity and variability of this disease during pregnancy, there is a compelling need to review current evidence to guide clinical practice and improve maternal and neonatal outcomes.Areas covered: This narrative review consolidates recent literature from database inception to June 2025, focusing on disease course, reproductive implications, and obstetric outcomes in women with BD. It evaluates the safety of immunosuppressive therapies during conception, pregnancy, and lactation. The review highlights key aspects such as preconception planning, disease monitoring, delivery considerations, and postpartum care, drawing from a broad spectrum of clinical research, guidelines, and expert opinions.Expert opinion: The current evidence suggests that with personalized, multidisciplinary care and careful medication management, many women with BD can experience successful pregnancies. While existing data support the safety of several therapies and highlight the importance of preconception counseling, significant gaps remain due to limited high-quality prospective studies. Advancements in understanding disease mechanisms, developing standardized protocols, and establishing evidence-based guidelines are necessary to optimize care and further improve reproductive outcomes in this patient population.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"545-555"},"PeriodicalIF":4.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intensive care unit acquired weakness: an update in the context of respiratory virus infection. 重症监护病房获得性弱点：呼吸道病毒感染背景下的最新情况。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-05-01 Epub Date: 2026-05-25 DOI: 10.1080/1744666X.2026.2672491

Ruoyi Zheng, Mingkai Lin, Muzi Wen, Pei Shang, Hong-Liang Zhang

{"title":"Intensive care unit acquired weakness: an update in the context of respiratory virus infection.","authors":"Ruoyi Zheng, Mingkai Lin, Muzi Wen, Pei Shang, Hong-Liang Zhang","doi":"10.1080/1744666X.2026.2672491","DOIUrl":"10.1080/1744666X.2026.2672491","url":null,"abstract":"Introduction: Intensive care unit-acquired weakness (ICUAW) is one of the most common neuromuscular impairments featuring symmetric and generalized weakness, and typically occurs in critically ill patients, particularly those with sepsis. Mechanistically, ICUAW shares overlapping immunological networks with respiratory viruses. While accumulating evidence supports an association between Guillain-Barré syndrome (GBS) and respiratory viruses, the causal relationship between ICUAW and these pathogens has not been sufficiently documented.Areas covered: This review summarizes current knowledge on the classification, diagnosis, and management of ICUAW, with a focus on its potential association with respiratory viruses. Relevant literature was collected from PubMed, Web of Science, Cochrane Library, and Google Scholar, focusing on English-language studies published between January 2019 and March 2026. This review addressed differential diagnostic challenges, potential pathogenic mechanisms, therapeutic interventions, and preventive strategies of ICUAW.Expert opinion: Emerging evidence suggests that respiratory viruses may exacerbate ICUAW, highlighting timely interventions combining biomarkers such as Interleukin (IL)-6 and Growth Differentiation Factor (GDF)-15 as promising therapeutic targets. Standardization of diagnostic criteria, refinement of animal models, and individualized rehabilitation strategies are warranted. Future studies on ICUAW should emphasize early assessment of muscle strength, evaluation of nutritional therapy efficacy, and prevention of complications.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"481-497"},"PeriodicalIF":4.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147948184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary biliary cholangitis: current insights and novel therapies. 原发性胆管炎：目前的见解和新的治疗方法。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-05-01 Epub Date: 2026-05-19 DOI: 10.1080/1744666X.2026.2672493

Alessandro Granito, Georgios Pappas, Lucia Napoli, Benedetta Stefanini, Daniela Tirotta, Paolo Muratori

{"title":"Primary biliary cholangitis: current insights and novel therapies.","authors":"Alessandro Granito, Georgios Pappas, Lucia Napoli, Benedetta Stefanini, Daniela Tirotta, Paolo Muratori","doi":"10.1080/1744666X.2026.2672493","DOIUrl":"10.1080/1744666X.2026.2672493","url":null,"abstract":"Introduction: Primary biliary cholangitis (PBC) may present asymptomatically or with potentially debilitating symptoms and can progress to cirrhosis despite first-line ursodeoxycholic acid (UDCA) therapy. A subset of patients exhibits inadequate response or intolerance, necessitating novel targeted approaches and a personalized management paradigm.Areas covered: This review synthesizes recent literature on PBC, highlighting a new treatment approach centered on a finer prognostic characterization of patients at diagnosis and throughout follow-up. This approach enables the identification of high-risk phenotypes and variant forms, including PBC with autoimmune hepatitis features and premature ductopenic PBC which adversely influence UDCA responsiveness.We explore the mechanisms and efficacy of newly approved second-line therapies, and other emerging investigational agents. The urgent need for effective therapies for still difficult-to-treat symptoms such as pruritus and fatigue is also discussed.Expert opinion: The current PBC treatment paradigm necessitates a transition from reactive, failure-guided management toward prognostically based and individualized therapeutic regimens. Novel therapies hold the potential to enable more tailored clinical strategies, aiming for both robust biochemical responses and improved quality of life by alleviating symptom burden. Crucially, real-world evidence is essential for validating registrative trial findings and assessing long-term disease evolution, particularly in patient subgroups that are underrepresented within pivotal clinical trials.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"519-543"},"PeriodicalIF":4.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147867289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial for exploring understudied inflammatory diseases. 探索未被充分研究的炎症性疾病的社论。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-05-01 Epub Date: 2026-05-18 DOI: 10.1080/1744666X.2026.2672492

Thomas G Forsthuber, Itay Raphael

引用次数: 0

Reconsidering the interpretation of polyautoimmunity in chronic immune-mediated neuropathies: association, misclassification, and clinical implications. 重新考虑慢性免疫介导的神经病变中多重自身免疫的解释：关联、错误分类和临床意义。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-05-01 Epub Date: 2026-05-17 DOI: 10.1080/1744666X.2026.2676689

Mehmet Serkan Kılıçoğlu

引用次数: 0

Multi-class classification of autoimmune skin disease by efficient localization of overlapped lesion boundaries using SAM. 自身免疫性皮肤病的多类别分类利用SAM有效定位重叠病变边界。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-04-01 Epub Date: 2026-04-26 DOI: 10.1080/1744666X.2026.2663042

A Jasmine Gilda, T Sethukarasi

{"title":"Multi-class classification of autoimmune skin disease by efficient localization of overlapped lesion boundaries using SAM.","authors":"A Jasmine Gilda, T Sethukarasi","doi":"10.1080/1744666X.2026.2663042","DOIUrl":"10.1080/1744666X.2026.2663042","url":null,"abstract":"Background: Detection of Autoimmune skin disease is found challenging due to overlapping features and irregular skin lesion boundaries. Although numerous deep learning models have been proposed for skin disease classification, most are primarily designed for general skin lesions and do not capture the complex and irregular visual characteristics specific to autoimmune skin conditions.Research design and methods: The proposed study develops a hybrid deep learning model, AutoImmune-HybridNet, that uses the Segment Anything Model for intelligent isolation of lesion regions, and ResNet50 with a deformable attention transformer for adaptively modeling the irregular shapes and spatial patterns of autoimmune skin lesions. A deformable attention transformer is improved with contrastive learning and the focal loss function to enhance feature discrimination among visually similar conditions. Explainability is incorporated with uncertainty estimation to ensure reliable predictions.Results: The AutoImmune-HybridNet was evaluated on a Human Skin Diseases dataset, and the model achieved an accuracy of 98%, which is better than currently available approaches.Conclusions: The proposed explainable deep learning framework effectively classifies multiple autoimmune skin diseases while providing an interpretable visualization. Limitations include dataset size and reliance on image-only data will be addressed in future work using multi-modal clinical information.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"429-439"},"PeriodicalIF":4.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing response to biological therapies in severe asthma. 评估严重哮喘患者对生物疗法的反应。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-04-01 Epub Date: 2026-04-03 DOI: 10.1080/1744666X.2026.2655162

Angelantonio Maglio, Carolina Vitale, Luisa Oriana D'Auria, Valeria Longobardi, Antonio Franzese, Corrado Pelaia, Girolamo Pelaia, Alessandro Vatrella

{"title":"Assessing response to biological therapies in severe asthma.","authors":"Angelantonio Maglio, Carolina Vitale, Luisa Oriana D'Auria, Valeria Longobardi, Antonio Franzese, Corrado Pelaia, Girolamo Pelaia, Alessandro Vatrella","doi":"10.1080/1744666X.2026.2655162","DOIUrl":"10.1080/1744666X.2026.2655162","url":null,"abstract":"Introduction: The management of severe asthma has shifted toward precision medicine, with clinical remission emerging as the ultimate therapeutic goal. This review evaluates the transition from predicting treatment response to achieving sustained remission through biologics.Areas covered: A comprehensive literature search was conducted in PubMed and Embase for articles published between January 2015 and February 2026. Keywords included 'severe asthma,' 'biologic therapies,' 'clinical remission,' and 'T2 biomarkers.' We analyze the predictive value of blood eosinophils (BEC), FeNO, and emerging indicators like CT-based mucus plugs. The review synthesizes data on 'super-responders' and the integration of real-world evidence into clinical practice.Expert opinion: Achieving clinical remission requires a multidimensional assessment beyond symptom control, including lung function stability and OCS elimination. Future management will likely focus on 'disease modification' and early biologic intervention. The identification of specific phenotypes, such as those with high mucus-plug burdens, will allow for more tailored therapy. However, standardized criteria for 'remission off-treatment' remain the primary challenge for the next decade of respiratory research.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"381-392"},"PeriodicalIF":4.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0